derma13gam2dec13.htm
|
UNITED STATES
|
|
SECURITIES AND EXCHANGE COMMISSION
|
|
Washington, D.C. 20549
|
| |
| |
|
SCHEDULE 13G
|
| |
| |
|
Under the Securities Exchange Act of 1934
|
|
(Amendment No. 2)*
|
| |
| |
|
DERMA SCIENCES, INC.
|
|
(Name of Issuer)
|
| |
|
CLASS COMMON STOCK, $0.01 PAR VALUE PER SHARE
|
|
(Title of Class of Securities)
|
| |
|
249827502
|
|
(CUSIP Number)
|
| |
|
December 31, 2013
|
|
(Date of Event Which Requires Filing of this Statement)
|
| |
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. 249827502
|
| |
|
(1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons (entities only):
|
| |
|
12 West Capital Management LP
|
| |
| |
|
(2) Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
|
| (3) SEC Use Only |
| |
| |
|
(4) Citizenship or Place of Organization: Delaware, United States
|
| |
| |
|
|
|
|
Number of Shares Beneficially Owned
|
|
|
|
|
by Each Reporting Person With
|
(5) Sole Voting Power:
|
0**
|
|
| |
(6) Shared Voting Power:
|
0**
|
|
| |
(7) Sole Dispositive Power:
|
0**
|
|
| |
(8) Shared Dispositive Power:
|
0**
|
|
| |
|
(9) Aggregate Amount Beneficially Owned by Each Reporting Person: 0**
|
| |
| |
|
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):
|
| |
| |
|
(11) Percent of Class Represented by Amount in Row (9): 0.0%**
|
| |
| |
|
(12) Type of Reporting Person (See Instructions): IA
|
| |
**12 West Capital Management LP (“12 West Management”) serves as the investment manager to 12 West Capital Fund LP, a Delaware limited partnership (“12 West Onshore Fund”), and 12 West Capital Offshore Fund LP, a Cayman Islands exempted limited partnership (“12 West Offshore Fund”), and possesses the sole power to vote and the sole power to direct the disposition of all securities of Derma Sciences, Inc. (the “Company”) held by 12 West Onshore Fund and 12 West Offshore Fund. Joel Ramin, as the sole member of 12 West Capital Management, LLC, the general partner of 12 West Management, possesses the voting and dispositive power with respect to all securities beneficially owned by 12 West Management.
As of December 31, 2013, 12 West Onshore Fund held zero (0) shares of common stock of the Company, par value $0.01 per share (the “Common Stock”), and 12 West Offshore Fund held zero (0) shares of Common Stock.
Based on information disclosed by the Company in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2013, filed with the Securities and Exchange Commission on November 12, 2013, there were 17,285,084 shares of Common Stock outstanding as of November 11, 2013. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, 12 West Management is deemed to beneficially own zero (0) shares of Common Stock, or 0.0% of the shares of Common Stock deemed issued and outstanding as of December 31, 2013.
|
Item 1(a) Name Of Issuer: Derma Sciences, Inc.
|
| |
|
Item 1(b) Address of Issuer’s Principal Executive Offices:
|
| |
|
| |
214 Carnegie Center
|
| |
Suite 300 |
| |
Princeton, New Jersey 08540
|
| |
| |
|
Item 2(a) Name of Person Filing:
|
| |
| 12 West Capital Management LP |
| |
|
Item 2(b) Address of Principal Business Office or, if None, Residence:
|
| |
| |
90 Park Avenue
|
| |
41st Floor |
| |
New York, New York 10016
|
| |
|
Item 2(c) Citizenship:
|
| |
| 12 West Capital Management LP is a Delaware limited partnership. |
| |
|
Item 2(d) Title of Class of Securities: Class Common Stock, $0.01 par value per share.
|
| |
|
Item 2(e) CUSIP No.: 249827502
|
| |
| |
|
Item 3. If This Statement Is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:
|
| |
| |
Not Applicable.
|
|
Item 4. Ownership.
|
| |
| |
(a) Amount Beneficially Owned:
|
|
|
| |
|
|
|
| |
(b) Percent of Class:
|
0.0%**
|
|
| |
|
|
|
| |
(c) Number of Shares as to which such person has:
|
|
|
| |
|
|
|
| |
|
(i) sole power to vote or to direct the vote:
|
|
|
| |
|
|
|
|
| |
|
(ii) shared power to vote or to direct the vote:
|
0**
|
|
| |
|
|
|
|
| |
|
(iii) sole power to dispose or to direct the disposition of:
|
|
|
| |
|
|
|
|
| |
|
(iv) shared power to dispose or to direct the disposition of:
|
0**
|
|
_____________
**12 West Capital Management LP (“12 West Management”) serves as the investment manager to 12 West Capital Fund LP, a Delaware limited partnership (“12 West Onshore Fund”), and 12 West Capital Offshore Fund LP, a Cayman Islands exempted limited partnership (“12 West Offshore Fund”), and possesses the sole power to vote and the sole power to direct the disposition of all securities of Derma Sciences, Inc. (the “Company”) held by 12 West Onshore Fund and 12 West Offshore Fund. Joel Ramin, as the sole member of 12 West Capital Management, LLC, the general partner of 12 West Management, possesses the voting and dispositive power with respect to all securities beneficially owned by 12 West Management.
As of December 31, 2013, 12 West Onshore Fund held zero (0) shares of common stock of the Company, par value $0.01 per share (the “Common Stock”), and 12 West Offshore Fund held zero (0) shares of Common Stock.
Based on information disclosed by the Company in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2013, filed with the Securities and Exchange Commission on November 12, 2013, there were 17,285,084 shares of Common Stock outstanding as of November 11, 2013. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, 12 West Management is deemed to beneficially own zero (0) shares of Common Stock, or 0.0% of the shares of Common Stock deemed issued and outstanding as of December 31, 2013.
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: [x].
Item 6. Ownership of More Than Five Percent on Behalf of Another Person
Not Applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
Not Applicable.
Item 8. Identification and Classification of Members of the Group
Not Applicable.
Item 9. Notice of Dissolution of Group
Not Applicable.
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| |
|
February 14, 2014
|
|
|
| |
|
|
|
|
| |
|
12 WEST CAPITAL MANAGEMENT LP |
|
|
| |
|
|
|
|
| |
By:
|
12 WEST CAPITAL MANAGEMENT, LLC,
|
|
|
| |
|
its General Partner |
|
|
| |
|
|
|
|
| |
|
By: |
/s/ Joel Ramin |
|
| |
|
|
Joel Ramin, |
|
| |
|
|
its Sole Member |
|
Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001)